Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus PHENAPHEN W CODEINE NO 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus PHENAPHEN W CODEINE NO 4.
METHADOSE vs PHENAPHEN W/ CODEINE NO. 4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Phenaphen w/ Codeine No. 4 contains acetaminophen and codeine. Acetaminophen inhibits prostaglandin synthesis in the CNS, reducing pain and fever. Codeine, an opioid prodrug, is converted to morphine via CYP2D6 and binds to mu-opioid receptors, inhibiting ascending pain pathways.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
1-2 tablets (300-600 mg acetaminophen / 30-60 mg codeine phosphate) orally every 4 hours as needed for pain; maximum 12 tablets per day.
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Codeine: 2.5-3.5 h; morphine: 2-4 h; clinically, analgesia correlates with morphine levels
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Renal: 90-100% as codeine and metabolites (codeine: 5-15%, morphine: 10%, norcodeine: 10%, morphine-3-glucuronide: 50%, morphine-6-glucuronide: <5%); biliary/fecal: minimal (<5%)
Category C
Category D/X
Opioid Agonist
Opioid Agonist